In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of Steroids

Benjamin Besse; Jordi Remon

doi:10.1016/j.jtho.2019.07.029

In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of Steroids

Benjamin Besse, Jordi Remon

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

langue originale	Anglais
Pages (de - à)	e260-e261
journal	Journal of Thoracic Oncology
Volume	14
Numéro de publication	11
Les DOIs	https://doi.org/10.1016/j.jtho.2019.07.029
état	Publié - 1 nov. 2019

Accès au document

10.1016/j.jtho.2019.07.029

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{2ba6a188befe45e1a5fcbf56022e4055,

title = "In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of Steroids",

author = "Benjamin Besse and Jordi Remon",

note = "Funding Information: Disclosure: Dr. Remon reports personal fees from MSD and Boehringer Ingelheim for serving on advisory boards, speaker fees from Pfizer, personal fees and nonfinancial support from OSE Immunotherapeutics, personal fees and reimbursement for travel expenses from BMS and AstraZeneca, and reimbursement for travel expenses from Roche outside the submitted work. Dr. Besse reports grants from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Blueprint Medicines, BMS, Celgene, Cristal Therapeutics, Eli Lilly, GSK, Ignyta, Ipsen, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE Immunopharmaceutics, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma outside the submitted work.",

year = "2019",

month = nov,

day = "1",

doi = "10.1016/j.jtho.2019.07.029",

language = "English",

volume = "14",

pages = "e260--e261",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

number = "11",

}

In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of Steroids. / Besse, Benjamin; Remon, Jordi.
Dans: Journal of Thoracic Oncology, Vol 14, Numéro 11, 01.11.2019, p. e260-e261.

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

TY - JOUR

T1 - In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy

T2 - Forcing on Organ-Specific irAEs and the Critical Role of Steroids

AU - Besse, Benjamin

AU - Remon, Jordi

N1 - Funding Information: Disclosure: Dr. Remon reports personal fees from MSD and Boehringer Ingelheim for serving on advisory boards, speaker fees from Pfizer, personal fees and nonfinancial support from OSE Immunotherapeutics, personal fees and reimbursement for travel expenses from BMS and AstraZeneca, and reimbursement for travel expenses from Roche outside the submitted work. Dr. Besse reports grants from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Blueprint Medicines, BMS, Celgene, Cristal Therapeutics, Eli Lilly, GSK, Ignyta, Ipsen, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE Immunopharmaceutics, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma outside the submitted work.

PY - 2019/11/1

Y1 - 2019/11/1

UR - http://www.scopus.com/inward/record.url?scp=85073740992&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2019.07.029

DO - 10.1016/j.jtho.2019.07.029

M3 - Letter

C2 - 31668327

AN - SCOPUS:85073740992

SN - 1556-0864

VL - 14

SP - e260-e261

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 11

ER -